A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

• Status: Completed
• Trial end date: 2017-12-20
• Target enrollment: 0
• Participant gender: All

Summary

Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Hydroxyitraconazole; Itraconazole; Linrodostat; Rifampin

Criteria

Inclusion Criteria:

• Body mass index 18.0 to 32.0 kg/m2, inclusive

• Must have normal renal function demonstrated by GFR, calculated by Chronic Kidney Disease Epidemiology Collaboration formula

• Women must not be of childbearing potential (cannot become pregnant)

Exclusion Criteria:

• Any significant acute or chronic medical illness

• History of glucose-6-phosphodiesterase (G6PD) deficiency

• Personal or family history of cytochrome b5 reductase deficiency

Other protocol defined inclusion / exclusion criteria could apply